Zimmer, L.(2014). Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. Journal of Clinical Oncology, 32(15_suppl), 9031-9031. doi:10.1200/jco.2014.32.15_suppl.9031

Zimmer, Lisa. "Open-label, Multicenter, Single-arm Phase II Study (DeCOG-Trial) to Further Evaluate the Efficacy and Safety of Ipilimumab in Patients With Cutaneous Melanoma and Rare Subgroups". Journal of Clinical Oncology, 32.15_suppl ( 2014 ): 9031-9031.